These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 23900211)

  • 1. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
    Wang J; Li L; Xu M; Rong R; Zhu T
    Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.
    He S; Wang J; Kato K; Xie F; Varambally S; Mineishi S; Kuick R; Mochizuki K; Liu Y; Nieves E; Mani RS; Chinnaiyan AM; Marquez VE; Zhang Y
    Blood; 2012 Feb; 119(5):1274-82. PubMed ID: 22117046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
    Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose 5-Aza and DZnep Alleviate Acute Graft-
    Wang QY; Liu HH; Dong YJ; Liang ZY; Yin Y; Liu W; Wang QY; Wang Q; Sun YH; Xu WL; Han N; Li Y; Ren HY
    Front Immunol; 2022; 13():780708. PubMed ID: 35281001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.
    He S; Cao Q; Qiu Y; Mi J; Zhang JZ; Jin M; Ge H; Emerson SG; Zhang Y; Zhang Y
    J Immunol; 2008 Dec; 181(11):7581-92. PubMed ID: 19017947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facilitating cells as a venue to establish mixed chimerism and tolerance.
    Jacquet EG; Schanie CL; Fugier-Vivier I; Willer SS; Ildstad ST
    Pediatr Transplant; 2003 Oct; 7(5):348-57. PubMed ID: 14738294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation.
    Alahmari B; Cooper M; Ziga E; Ritchey J; DiPersio JF; Choi J
    PLoS One; 2018; 13(11):e0207609. PubMed ID: 30452487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
    Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
    Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning.
    Seung E; Mordes JP; Rossini AA; Greiner DL
    J Clin Invest; 2003 Sep; 112(5):795-808. PubMed ID: 12952928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iNKT cell activation plus T-cell transfer establishes complete chimerism in a murine sublethal bone marrow transplant model.
    Ishii R; Hirai T; Miyairi S; Omoto K; Okumi M; Ishii Y; Tanabe K
    Am J Transplant; 2018 Feb; 18(2):328-340. PubMed ID: 28766890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.
    Hossain MS; Jaye DL; Pollack BP; Farris AB; Tselanyane ML; David E; Roback JD; Gewirtz AT; Waller EK
    J Immunol; 2011 Nov; 187(10):5130-40. PubMed ID: 22013117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
    Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
    Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.
    Sadeghi B; Al-Hashmi S; Hassan Z; Rozell B; Concha H; Lundmark C; Grönvik KO; Abedi-Valugerdi M; Hassan M
    Clin Dev Immunol; 2010; 2010():142943. PubMed ID: 21197273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.
    Huang Q; He S; Tian Y; Gu Y; Chen P; Li C; Huang J; Liu Y; Yu H; Jin M; Hu S; Tong Q; Ma A; Jin J; Hexner E; Fung H; Reshef R; Zhang Y; Zhang Y
    Blood; 2017 May; 129(20):2737-2748. PubMed ID: 28246193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.